{"transactions":[{"id":4624150,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":60984,"kind":"person","name":"CARR EDWARD","position":1,"cik":"0001273351","reported_name":"CARR EDWARD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T20:36:21.000Z","date":"2026-09-17","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":43818,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001273351-26-000006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000127335126000006/ownership.xml","form_type":"4"}},{"id":4624149,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":60984,"kind":"person","name":"CARR EDWARD","position":1,"cik":"0001273351","reported_name":"CARR EDWARD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T20:36:21.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":700,"price":104.39,"value":73073.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.17 to $104.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001273351-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000127335126000006/ownership.xml","form_type":"4"}},{"id":4624148,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":60984,"kind":"person","name":"CARR EDWARD","position":1,"cik":"0001273351","reported_name":"CARR EDWARD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T20:36:21.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":103.2,"value":113520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.05 to $103.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":700,"source":{"system":"sec-edgar","filing":"0001273351-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000127335126000006/ownership.xml","form_type":"4"}},{"id":4624147,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":60984,"kind":"person","name":"CARR EDWARD","position":1,"cik":"0001273351","reported_name":"CARR EDWARD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T20:36:21.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":3501,"price":102.39,"value":358467.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.99 to $102.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1800,"source":{"system":"sec-edgar","filing":"0001273351-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000127335126000006/ownership.xml","form_type":"4"}},{"id":4624146,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":60984,"kind":"person","name":"CARR EDWARD","position":1,"cik":"0001273351","reported_name":"CARR EDWARD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T20:36:21.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":6771,"price":101.37,"value":686376.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.99 to $101.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":5301,"source":{"system":"sec-edgar","filing":"0001273351-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000127335126000006/ownership.xml","form_type":"4"}},{"id":4624145,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":60984,"kind":"person","name":"CARR EDWARD","position":1,"cik":"0001273351","reported_name":"CARR EDWARD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T20:36:21.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":7928,"price":100.43,"value":796209.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.98 to $100.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":12072,"source":{"system":"sec-edgar","filing":"0001273351-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000127335126000006/ownership.xml","form_type":"4"}},{"id":4624144,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":60984,"kind":"person","name":"CARR EDWARD","position":1,"cik":"0001273351","reported_name":"CARR EDWARD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T20:36:21.000Z","date":"2026-09-17","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":17.88,"value":357600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001273351-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000127335126000006/ownership.xml","form_type":"4"}},{"id":2398,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:30:11.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":9375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":87500,"derivative":{"exercise_price":22.07,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0001992260-26-000009","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000009/ownership.xml","form_type":"4"}},{"id":2397,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:30:11.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":6249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":41676,"derivative":{"exercise_price":21.77,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":6249},"source":{"system":"sec-edgar","filing":"0001992260-26-000009","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000009/ownership.xml","form_type":"4"}},{"id":2396,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:30:11.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":56776,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001992260-26-000009","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000009/ownership.xml","form_type":"4"}},{"id":2395,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-03T20:30:11.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":13309,"price":106.74,"value":1420602.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.53 to $107.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001992260-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000009/ownership.xml","form_type":"4"}},{"id":2394,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-03T20:30:11.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":7215,"price":106.25,"value":766593.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.53 to $106.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":17309,"source":{"system":"sec-edgar","filing":"0001992260-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000009/ownership.xml","form_type":"4"}},{"id":2393,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-03T20:30:11.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":2600,"price":105.19,"value":273494.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.50 to $105.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":24524,"source":{"system":"sec-edgar","filing":"0001992260-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000009/ownership.xml","form_type":"4"}},{"id":2392,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-03T20:30:11.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":9375,"price":22.07,"value":206906.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."}],"balance_after":27124,"source":{"system":"sec-edgar","filing":"0001992260-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000009/ownership.xml","form_type":"4"}},{"id":2391,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-03T20:30:11.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":6249,"price":21.77,"value":136040.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."}],"balance_after":17749,"source":{"system":"sec-edgar","filing":"0001992260-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000009/ownership.xml","form_type":"4"}},{"id":2390,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-03T20:30:11.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":17.88,"value":134100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."}],"balance_after":11500,"source":{"system":"sec-edgar","filing":"0001992260-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000009/ownership.xml","form_type":"4"}},{"id":681410,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T22:02:39.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":false,"shares":2778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":19445,"derivative":{"exercise_price":18.36,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":2778},"source":{"system":"sec-edgar","filing":"0001688199-26-000006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000006/ownership.xml","form_type":"4"}},{"id":681409,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T22:02:39.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":2778,"price":117.55,"value":326553.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.01 to $117.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001688199-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000006/ownership.xml","form_type":"4"}},{"id":681408,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T22:02:39.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":true,"shares":2778,"price":18.36,"value":51004.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."}],"balance_after":2778,"source":{"system":"sec-edgar","filing":"0001688199-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000006/ownership.xml","form_type":"4"}},{"id":686919,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:30:03.000Z","date":"2026-08-13","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":73240,"derivative":{"exercise_price":18.17,"expiration_date":"2033-06-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001778623-26-000009","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000009/ownership.xml","form_type":"4"}},{"id":686918,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-14T20:30:03.000Z","date":"2026-08-13","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":18.17,"value":272550.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001778623-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000009/ownership.xml","form_type":"4"}},{"id":690776,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":24608,"kind":"person","name":"McGeorge Anne","position":1,"cik":"0001779934","reported_name":"McGeorge Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T21:15:25.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026."}],"balance_after":0,"derivative":{"exercise_price":11.2,"exercise_date":"2024-05-23","expiration_date":"2033-09-10","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001779934-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177993426000004/ownership.xml","form_type":"4"}},{"id":690775,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":24608,"kind":"person","name":"McGeorge Anne","position":1,"cik":"0001779934","reported_name":"McGeorge Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T21:15:25.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026."}],"balance_after":0,"derivative":{"exercise_price":19.36,"exercise_date":"2023-06-28","expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001779934-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177993426000004/ownership.xml","form_type":"4"}},{"id":690774,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":24608,"kind":"person","name":"McGeorge Anne","position":1,"cik":"0001779934","reported_name":"McGeorge Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:15:25.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":700,"price":111.41,"value":77987.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.15 to $111.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001779934-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177993426000004/ownership.xml","form_type":"4"}},{"id":690773,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":24608,"kind":"person","name":"McGeorge Anne","position":1,"cik":"0001779934","reported_name":"McGeorge Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:15:25.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":110.64,"value":110640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.05 to $111.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":700,"source":{"system":"sec-edgar","filing":"0001779934-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177993426000004/ownership.xml","form_type":"4"}},{"id":690772,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":24608,"kind":"person","name":"McGeorge Anne","position":1,"cik":"0001779934","reported_name":"McGeorge Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:15:25.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":109.3,"value":196740.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.89 to $109.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1700,"source":{"system":"sec-edgar","filing":"0001779934-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177993426000004/ownership.xml","form_type":"4"}},{"id":690771,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":24608,"kind":"person","name":"McGeorge Anne","position":1,"cik":"0001779934","reported_name":"McGeorge Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:15:25.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":2800,"price":108.38,"value":303464.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.84 to $108.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3500,"source":{"system":"sec-edgar","filing":"0001779934-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177993426000004/ownership.xml","form_type":"4"}},{"id":690770,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":24608,"kind":"person","name":"McGeorge Anne","position":1,"cik":"0001779934","reported_name":"McGeorge Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:15:25.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":1450,"price":107.58,"value":155991.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.79 to $107.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":6300,"source":{"system":"sec-edgar","filing":"0001779934-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177993426000004/ownership.xml","form_type":"4"}},{"id":690769,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":24608,"kind":"person","name":"McGeorge Anne","position":1,"cik":"0001779934","reported_name":"McGeorge Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:15:25.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":6500,"price":11.2,"value":72800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001779934-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177993426000004/ownership.xml","form_type":"4"}},{"id":690768,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":24608,"kind":"person","name":"McGeorge Anne","position":1,"cik":"0001779934","reported_name":"McGeorge Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:15:25.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":19.36,"value":24200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026."}],"balance_after":1250,"source":{"system":"sec-edgar","filing":"0001779934-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177993426000004/ownership.xml","form_type":"4"}},{"id":690767,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":2777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":22223,"derivative":{"exercise_price":18.36,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":2777},"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690766,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":397,"price":111.77,"value":44372.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.57 to $111.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690765,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":470,"price":111.05,"value":52193.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.56 to $111.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":397,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690764,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":272,"price":109.96,"value":29909.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.55 to $110.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":867,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690763,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":831,"price":108.95,"value":90537.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.54 to $109.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1139,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690762,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":737,"price":108.17,"value":79721.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.54 to $108.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1970,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690761,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":70,"price":107.11,"value":7497.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.50 to $107.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2707,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690760,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":2777,"price":18.36,"value":50985.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."}],"balance_after":2777,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690759,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":16167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":16167},"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690758,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":false,"shares":3833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":76167,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":3833},"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690757,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":16167,"price":110.38,"value":1784513.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.00 to $110.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690756,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":16167,"price":17.88,"value":289065.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."}],"balance_after":16167,"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690755,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":616,"price":111.18,"value":68486.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.08 to $111.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690754,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":3217,"price":110.61,"value":355832.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.07 to $111.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":616,"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690753,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":true,"shares":3833,"price":17.88,"value":68534.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."}],"balance_after":3833,"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":693076,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":false,"shares":126000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":160004,"derivative":{"exercise_price":8.44,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":126000},"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":693075,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":286004,"derivative":{"exercise_price":8.44,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":693074,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":21909,"price":108.72,"value":2381946.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.57 to $108.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":65292,"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":693073,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":104091,"price":107.96,"value":11237664.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.52 to $108.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":87102,"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":693072,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":800,"price":110.76,"value":88608.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026."}],"balance_after":191292,"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":693071,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":2536,"price":110.02,"value":279010.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.75 to $110.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":192092,"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":693070,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":2373,"price":109.1,"value":258894.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.74 to $109.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":194628,"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":693069,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":23907,"price":108.05,"value":2583151.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.68 to $108.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":197001,"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":693068,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":10384,"price":107.49,"value":1116176.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.68 to $107.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":220908,"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":693067,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":true,"shares":126000,"price":8.44,"value":1063440.0,"ownership":{"direct":true},"balance_after":231292,"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":693066,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":25437,"kind":"person","name":"Garcia Marino","position":1,"cik":"0001669866","reported_name":"Garcia Marino","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2026-08-07T22:30:37.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":8.44,"value":337600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026."}],"balance_after":105292,"source":{"system":"sec-edgar","filing":"0001669866-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000166986626000010/ownership.xml","form_type":"4"}},{"id":710611,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-13T21:00:07.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":false,"shares":31249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":68751,"derivative":{"exercise_price":21.77,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":31249},"source":{"system":"sec-edgar","filing":"0001992324-26-000008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000008/ownership.xml","form_type":"4"}},{"id":710610,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-07-13T21:00:07.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":5566,"price":101.97,"value":567565.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.95 to $102.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001992324-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000008/ownership.xml","form_type":"4"}},{"id":710609,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-07-13T21:00:07.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":15329,"price":101.24,"value":1551907.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.78 to $101.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":5566,"source":{"system":"sec-edgar","filing":"0001992324-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000008/ownership.xml","form_type":"4"}},{"id":710608,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-07-13T21:00:07.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":10354,"price":100.22,"value":1037677.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.75 to $100.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":20895,"source":{"system":"sec-edgar","filing":"0001992324-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000008/ownership.xml","form_type":"4"}},{"id":710607,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-07-13T21:00:07.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":true,"shares":31249,"price":21.77,"value":680290.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."}],"balance_after":31249,"source":{"system":"sec-edgar","filing":"0001992324-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000008/ownership.xml","form_type":"4"}},{"id":732100,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:30:09.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001778623-26-000005","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000005/ownership.xml","form_type":"4"}},{"id":732099,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-06-18T20:30:09.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":13229,"price":81.38,"value":1076576.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.00 to $81.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001778623-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000005/ownership.xml","form_type":"4"}},{"id":732098,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-06-18T20:30:09.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":16771,"price":80.34,"value":1347382.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.00 to $80.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":13229,"source":{"system":"sec-edgar","filing":"0001778623-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000005/ownership.xml","form_type":"4"}},{"id":732097,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-06-18T20:30:09.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":17.88,"value":536400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001778623-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000005/ownership.xml","form_type":"4"}},{"id":755209,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":9375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":96875,"derivative":{"exercise_price":22.07,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":755208,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":6249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":47925,"derivative":{"exercise_price":21.77,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":6249},"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":755207,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":6908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":64276,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":6908},"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":755206,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":3998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.44,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":3998},"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":755205,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":4159,"price":91.37,"value":380007.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.17 to $91.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":755204,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":16943,"price":90.72,"value":1537068.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.17 to $91.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8159,"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":755203,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":5428,"price":89.72,"value":487000.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.17 to $90.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":25102,"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":755202,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":9375,"price":22.07,"value":206906.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."}],"balance_after":30530,"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":755201,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":6249,"price":21.77,"value":136040.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."}],"balance_after":21155,"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":755200,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":6908,"price":17.88,"value":123515.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."}],"balance_after":14906,"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":755199,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":1814,"kind":"person","name":"Randhawa Simrat","position":1,"cik":"0001992260","reported_name":"Randhawa Simrat","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D"}}],"security":"Common Stock","published_at":"2026-06-02T23:00:06.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":3998,"price":8.44,"value":33743.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."}],"balance_after":7998,"source":{"system":"sec-edgar","filing":"0001992260-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992260/000199226026000006/ownership.xml","form_type":"4"}},{"id":765984,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:11.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001688199-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000002/ownership.xml","form_type":"4"}},{"id":765983,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:11.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001639860-26-000005","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000163986026000005/ownership.xml","form_type":"4"}},{"id":765982,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":24608,"kind":"person","name":"McGeorge Anne","position":1,"cik":"0001779934","reported_name":"McGeorge Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:09.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001779934-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177993426000002/ownership.xml","form_type":"4"}},{"id":765981,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:09.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001542650-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000154265026000002/ownership.xml","form_type":"4"}},{"id":765979,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44737,"kind":"person","name":"KANGO SUJAY","position":1,"cik":"0001336503","reported_name":"KANGO SUJAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:07.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001336503-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000133650326000002/ownership.xml","form_type":"4"}},{"id":765978,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:05.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001730615-26-000003","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000173061526000003/ownership.xml","form_type":"4"}},{"id":765988,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44740,"kind":"person","name":"Soteropoulos Paula","position":1,"cik":"0001692444","reported_name":"Soteropoulos Paula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:03.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001692444-26-000010","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692444/000169244426000010/ownership.xml","form_type":"4"}},{"id":784778,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44740,"kind":"person","name":"Soteropoulos Paula","position":1,"cik":"0001692444","reported_name":"Soteropoulos Paula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-11T21:00:13.000Z","date":"2026-05-08","kind":"exercise","planned":true,"acquired":false,"shares":599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of common stock underlying this stock option award vested as to 25% of the shares on April 6, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.44,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":599},"source":{"system":"sec-edgar","filing":"0001692444-26-000008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692444/000169244426000008/ownership.xml","form_type":"4"}},{"id":784777,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44740,"kind":"person","name":"Soteropoulos Paula","position":1,"cik":"0001692444","reported_name":"Soteropoulos Paula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T21:00:13.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":599,"price":85.47,"value":51196.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001692444-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692444/000169244426000008/ownership.xml","form_type":"4"}},{"id":784776,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44740,"kind":"person","name":"Soteropoulos Paula","position":1,"cik":"0001692444","reported_name":"Soteropoulos Paula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T21:00:13.000Z","date":"2026-05-08","kind":"exercise","planned":true,"acquired":true,"shares":599,"price":8.44,"value":5055.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025."}],"balance_after":599,"source":{"system":"sec-edgar","filing":"0001692444-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692444/000169244426000008/ownership.xml","form_type":"4"}},{"id":810393,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-10T20:52:24.000Z","date":"2026-04-09","kind":"exercise","planned":true,"acquired":false,"shares":8224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":71776,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":8224},"source":{"system":"sec-edgar","filing":"0001992324-26-000006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000006/ownership.xml","form_type":"4"}},{"id":810392,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-10T20:52:24.000Z","date":"2026-04-09","kind":"sale","planned":true,"acquired":false,"shares":8224,"price":89.84,"value":738844.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.75 to $89.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001992324-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000006/ownership.xml","form_type":"4"}},{"id":810391,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-10T20:52:24.000Z","date":"2026-04-09","kind":"exercise","planned":true,"acquired":true,"shares":8224,"price":17.88,"value":147045.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."}],"balance_after":8224,"source":{"system":"sec-edgar","filing":"0001992324-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000006/ownership.xml","form_type":"4"}},{"id":822882,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}},{"id":822881,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":false,"shares":74367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":10399,"derivative":{"exercise_price":8.44,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":74367},"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}},{"id":822880,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":7232,"price":85.54,"value":618625.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.25 to $85.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}},{"id":822879,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":19469,"price":84.57,"value":1646493.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.25 to $85.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":7232,"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}},{"id":822878,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":59800,"price":83.9,"value":5017220.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.25 to $84.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":26701,"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}},{"id":822877,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":2366,"price":82.84,"value":195999.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.25 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":86501,"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}},{"id":822876,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":800,"price":81.36,"value":65088.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.15 to $81.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":88867,"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}},{"id":822875,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":1485,"price":80.25,"value":119171.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.11 to $81.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":89667,"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}},{"id":822874,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":21825,"price":78.86,"value":1721119.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.74 to $79.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":91152,"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}},{"id":822873,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":1390,"price":78.33,"value":108878.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.74 to $78.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":112977,"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}},{"id":822872,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":30813,"kind":"person","name":"Savitz Ryan","position":1,"cik":"0001992324","reported_name":"Savitz Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2026-04-01T21:26:57.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":17.88,"value":715200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."}],"balance_after":114367,"source":{"system":"sec-edgar","filing":"0001992324-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000199232426000004/ownership.xml","form_type":"4"}}],"next_cursor":"2026-04-01T21:26:57.000000Z,822872"}